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Predicting Coronary Artery Aneurysms in Kawasaki Disease at a
North American Center: An Assessment of Baseline z Scores
Mary Beth F. Son, MD; Kimberlee Gauvreau, ScD; Susan Kim, MD, MMSc; Alexander Tang, BA; Fatma Dedeoglu, MD; David R. Fulton, MD;
Mindy S. Lo, MD, PhD; Annette L. Baker, RN, MSN, PNP; Robert P. Sundel, MD; Jane W. Newburger, MD, MPH
Background-—Accurate risk prediction of coronary artery aneurysms (CAAs) in North American children with Kawasaki disease
remains a clinical challenge. We sought to determine the predictive utility of baseline coronary dimensions adjusted for body
surface area (z scores) for future CAAs in Kawasaki disease and explored the extent to which addition of established Japanese risk
scores to baseline coronary artery z scores improved discrimination for CAA development.
Methods and Results-—We explored the relationships of CAA with baseline z scores; with Kobayashi, Sano, Egami, and Harada risk
scores; and with the combination of baseline z scores and risk scores. We deﬁned CAA as a maximum z score (zMax) ≥2.5 of the
left anterior descending or right coronary artery at 4 to 8 weeks of illness. Of 261 patients, 77 patients (29%) had a baseline zMax
≥2.0. CAAs occurred in 15 patients (6%). CAAs were strongly associated with baseline zMax ≥2.0 versus <2.0 (12 [16%] versus 3
[2%], respectively, P<0.001). Baseline zMax ≥2.0 had a C statistic of 0.77, good sensitivity (80%), and excellent negative predictive
value (98%). None of the risk scores alone had adequate discrimination. When high-risk status per the Japanese risk scores was
added to models containing baseline zMax ≥2.0, none were signiﬁcantly better than baseline zMax ≥2.0 alone.
Conclusions-—In a North American center, baseline zMax ≥2.0 in children with Kawasaki disease demonstrated high predictive
utility for later development of CAA. Future studies should validate the utility of our ﬁndings. ( J Am Heart Assoc. 2017;6:
e005378. DOI: 10.1161/JAHA.116.005378.)
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K awasaki disease (KD) is a vasculitis of medium and smallmuscular arteries that primarily affects young children
and has a predilection for the coronary arteries. Although the
majority of children with KD respond well to treatment with
intravenous immunoglobulin (IVIG), some develop coronary
artery aneurysms (CAAs), a potentially devastating conse-
quence of the disease that is associated with signiﬁcant
morbidity.1–3 Prior studies have reported that higher coronary
dimensions on the baseline echocardiogram (ie, at diagnosis)
are more common among children in whom CAAs evolve.4,5
Other risk factors for CAAs include the persistence or
recrudescence of fever after a single dose of IVIG (referred
to as IVIG resistance),6,7 male sex,8,9 age ≤12 months,9,10
Asian race,8,11 and delay in diagnosis.12–14
Three risk scores for the prediction of IVIG resistance have
been developed in Japan: the Kobayashi,15 Egami,16 and
Sano17 risk scores. The Harada risk score was devised to
identify indications for treatment with IVIG.18 Demographic,
clinical, and laboratory data points constitute the scores
(Table 1). Sleeper et al assessed the performance of the
Kobayashi, Sano, and Egami risk scores in the Pediatric Heart
Network data set and found that they had low sensitivity and
moderate speciﬁcity for predicting IVIG resistance in a North
American cohort.19 Tremoulet et al described similar ﬁndings
with the application of the Egami risk score to a cohort from
San Diego, California.20 The Harada risk score has been
applied to a US population and was found to be 90% sensitive
for identifying children at high risk of CAAs but had low
speciﬁcity (51%) and low positive predictive value (PPV;
19%).21
Because the performance of the established risk scores in
North American cohorts has been unsatisfactory, better
methods of identifying children at the highest risk of
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aneurysm formation are needed. Such identiﬁcation would
beneﬁt the individual patient via early risk identiﬁcation and
tailoring of treatment and potentially allow for the design of
well-powered treatment trials to determine optimal therapy in
KD.
In the current single-center study, we sought to deter-
mine the predictive utility of baseline echocardiography for
later CAA and to assess test characteristics of baseline
coronary dimensions adjusted for body surface area (ie, z
scores). We further explored the extent to which addition of
variables in established Japanese risk scores to baseline
coronary artery z scores could improve discrimination
between children who develop coronary aneurysms and
those who do not.
Methods
Identiﬁcation of Cohort
Demographic, clinical, laboratory, and echocardiographic data
were abstracted for patients diagnosed with KD at a single
academic center from January 1, 2006, through May 1, 2014.
Race and ethnicity were extracted from the electronic medical
record, which is populated with information provided by the
parents on registration with the hospital. We collected this
information because prior studies have indicated that patients
of Asian descent8,11 or Hispanic ethnicity11 are at increased
risk of poor coronary outcomes. Patients with incomplete
KD22 were included. We excluded patients who had at least
one of the following criteria: (1) a second episode of KD; (2)
presentation at our center for a second opinion; (3) ﬁrst
evaluation at our center in the subacute phase of illness; (4)
no or unknown treatment with IVIG; (5) missing all laboratory
data for calculation of established Japanese risk scores; (6)
ﬁrst laboratory studies obtained ≥10 days after fever onset or
≥1 day after IVIG administration; (7) no echocardiography at
baseline, meaning obtained either before IVIG administration
or within 2 days of ﬁrst IVIG treatment; or (8) no echocar-
diographic data available in the 4 to 8 weeks after illness
onset.
Coronary artery dimensions from the left anterior
descending artery and the proximal right coronary artery
were normalized for body surface area (z scores) using the
Boston formula.5 Coronary artery z scores were calculated
for baseline studies and for studies obtained 4 to 8 weeks
Table 1. Characteristics of Japanese Risk Scores
Kobayashi, Cutoff for High Risk: ≥4 Sano, Cutoff for High Risk: ≥2 Egami, Cutoff for High Risk: ≥3 Harada, Cutoff for High Risk: ≥4
Fever ≤4 d (2)* . . . Fever ≤4 d (1) . . .
Age ≤12 mo (1) . . . Age ≤6 mo (1) Age ≤12 mo (1)
. . . . . . . . . Male sex (1)
C-reactive protein ≥10 mg/dL (1) C-reactive protein ≥7 mg/dL (1) C-reactive protein ≥8 mg/dL (1) C-reactive protein >3 mg/dL (1)
Platelets ≤300 000/mm3 (1) . . . Platelets ≤300 000/mm3 (1) Platelets <350 000/lL (1)
AST ≥100 IU/L (2) AST ≥200 IU/L (1) ALT ≥80 IU/L (2) . . .
Sodium ≤133 mmol/L (2) . . . . . . . . .
Neutrophils ≥80% (2) . . . . . . White blood cell >12 000/lL (1)
. . . Total bilirubin ≥0.9 mg/dL (1) . . . . . .
. . . . . . . . . Albumin <3.5 g/L (1)
Hematocrit <35% (1)
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase.
*Number in parentheses indicates number of points awarded for each component to calculate risk score.
Clinical Perspective
What Is New?
• Accurate prediction of CAAs in North American children with
KD remains a clinical challenge.
• A baseline coronary artery z score ≥2.0 had higher
predictive utility for aneurysm development than demo-
graphic or laboratory variables or established Japanese risk
scores.
What Are the Clinical Implications?
• Because baseline z scores are quantitative measures that
are obtained in the routine care of patients with KD, our
ﬁndings raise the possibility that z scores may be used as an
imaging biomarker for the identiﬁcation of high-risk patients
with KD in North American populations.
• Early identiﬁcation of high-risk children may allow for
tailoring of treatment and design of well-powered clinical
trials to assess efﬁcacy of treatment regimens.
• Future studies should validate the utility of our ﬁndings.
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after illness onset. The maximum z score (zMax) was
deﬁned as the larger z score of the left anterior descending
or right coronary artery on a particular echocardiogram.
CAAs were deﬁned as a zMax ≥2.5 of the proximal right
coronary artery and/or proximal left anterior descending
artery at 4 to 8 weeks following fever onset. If multiple
echocardiograms were obtained in the 4- to 8-week time
period, we utilized the largest zMax from this window. For
those patients with CAA at 4 to 8 weeks, subsequent
echocardiograms were assessed for persistence or regres-
sion of the CAA.
Risk Scores
Clinical, demographic, and laboratory data points from our
cohort were used for calculation of published Japanese risk
scores15–18 (Table 1). Cut points speciﬁed by the authors of
each risk score were applied to determine whether a patient’s
risk was considered to be high or low.
Analysis
Demographic characteristics and echocardiographic data
were summarized using frequencies and percentages for
categorical variables and medians with ranges for continuous
variables. We compared proportions of patients with subse-
quent CAA for those with baseline zMax ≥2.0 versus <2.0,
baseline zMax of ≥2.5 versus <2.5, and baseline zMax of ≥3.0
versus <3.0 using the Fisher exact test. Similar analyses were
performed for each Japanese risk score, comparing high
versus low risk groups. Sensitivity, speciﬁcity, PPV, and
negative predictive value for CAA were calculated for baseline
zMax ≥2.0 and for each risk score. A z score >2.0 was not
selected because we wanted to minimize the false-negative
rate of our cutoff and maximize the detection of children who
are at risk for progressive coronary artery dilation. Odds ratios
for CAA were estimated using logistic regression models; the
discrimination for each model was quantiﬁed using the area
under the receiver operating characteristic curve (C statistic).
The C statistic is a measure of goodness-of-ﬁt for binary
outcomes in a logistic regression model. A C statistic of 0.5
means that the model has no ability to discriminate between
patients who do and do not experience the outcome; a value
of 1 means that the model predicts the outcome perfectly.
Increases in the C statistic when each Japanese risk score
was added to a model that already contained baseline zMax
≥2.0 were calculated. The improvement in risk prediction
when each risk score was included in combination with
baseline zMax was also assessed using the category-free net
reclassiﬁcation improvement (NRI).23 The NRI is the sum of
the net percentage of patients with CAA for whom the
predicted probability of the outcome increases when risk
score is added to baseline zMax and the net percentage of
patients without CAA for whom the predicted probability of
the outcome decreases when risk score is added; these net
percentages are also reported. The NRI takes values from 2
to 2, with higher positive values representing improved risk
prediction. Additional demographic and laboratory character-
istics were compared for patients with and without CAA, using
the Wilcoxon rank sum test for continuous variables and the
Fisher exact test for categorical variables. Associations of
these variables with CAA after adjusting for baseline zMax
were assessed using multivariable logistic regression models.
Forward stepwise selection was used, and P<0.05 was
required for retention in the ﬁnal model.
Approval from our institutional review board with a waiver
of informed consent was obtained for this project.
Results
A total of 504 patients were diagnosed with KD at our center
during the study period. After the exclusion criteria were
applied, 261 patients remained for analysis and formed the
cohort for this study (Table 2). All patients were treated within
10 days of fever onset; 67 patients (26%) required retreat-
ment for IVIG resistance (persistent or recrudescent fever
36 hours after completion of ﬁrst IVIG) and received >1 dose
of IVIG (Table 2). Of those patients retreated with IVIG, 18
Table 2. Baseline Characteristics of Cohort (n=261)
Variable n or median, (% or IQR)
Age at fever onset, y 3.2 (1.7, 5.2)
Male sex 169 (65)
Race
White 165 (63)
Black 29 (11)
Asian 44 (17)
Other, including >1 race 19 (7)
Not reported 4 (2)
Hispanic 35 (13)
Congenital heart disease 6 (2)
Days of fever 7 (6, 8)
Clinical criteria for KD
≤3 70 (27)
4 127 (49)
5 64 (25)
Retreatment with IVIG 67 (26)
Days from first to second treatment 2 (2, 3)
IQR indicates interquartile range; IVIG, intravenous immunoglobulin; KD, Kawasaki
disease.
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patients were also treated with corticosteroids and 5 patients
with inﬂiximab for persistent fever and/or expanding coronary
arteries. A comparison of baseline characteristics between
the cohort and the 70 patients who were excluded due to lack
of echocardiographic data at 4 to 8 weeks after illness onset
revealed no signiﬁcant differences (Table S1).
Baseline echocardiography was obtained either before IVIG
administration or within 2 days of ﬁrst IVIG treatment. Nearly
30% of patients (n=77) had a zMax ≥2.0, 21% had a z score
≥2.5 (n=55), and 15% (n=38) had a z score ≥3.0 (Figure). By 4
to 8 weeks after fever onset, 15 patients (6%) had CAA. Of
those, 12 had a zMax ≥2.0 at baseline. For nearly half of the
patients, (114/261, 44%), the baseline zMax was the largest z
score recorded for that patient within 8 weeks of illness
onset. Seven of the 15 patients with aneurysms at 4 to
8 weeks of illness had aneurysms that persisted at latest
follow-up (mean follow up: 6732 months; range:
19–98 months).
Baseline zMax ≥2.0 was strongly associated with aneurysm
development compared with a baseline zMax <2.0 (16%
versus 2%, P<0.001; Table 3), with a C statistic of 0.77 (95%
conﬁdence interval, 0.66–0.88; Table 4). We also calculated
sensitivity, speciﬁcity, PPV, and negative predictive value for
baseline zMax ≥2.0 and for the high-risk category of each of
the risk scores (Table 5). Sensitivity was quite good for a
baseline zMax ≥2.0 (80%) and excellent for the Harada risk
score (100%) but poor for the Kobayashi, Sano, and Egami risk
scores (21%, 13%, and 21%, respectively). A baseline zMax
≥2.0 had a speciﬁcity of 74%. Speciﬁcity ranged from low to
moderate across the Japanese risk scores, with the Harada
risk score having the lowest speciﬁcity (36%). PPV was low for
a baseline zMax ≥2.0 and for all risk scores, and conversely,
negative predictive value was >90% for a baseline zMax ≥2.0
and for all risk scores.
In contrast to baseline zMax ≥2.0, stratiﬁcation of patients
in high- versus low-risk groups using the criteria of the
Kobayashi, Sano, and Egami risk scores revealed no associ-
ation between high-risk status and CAA (Table 3), and they
demonstrated poor discrimination for CAA development
because they each had a C statistic <0.6 (Table 4). The
Harada score, however, was signiﬁcantly associated with CAA;
all aneurysms occurred in the high-risk group, with none in the
low-risk group (9% versus 0%, P=0.003; Table 3). A high-
versus low-risk status per the Harada score was not predictive
of aneurysm development in children who had a baseline
zMax <2 (2.6% versus 0%, P=0.3). In contrast, a high- versus
low-risk Harada score in children with a baseline zMax ≥2 was
signiﬁcantly associated with CAA (21.5% versus 0%, P=0.03).
To determine whether addition of the Japanese risk scores
to baseline zMax improved CAA prediction, we constructed
bivariate models that each included baseline zMax ≥2.0 plus
high-risk status for one of the risk scores. The absence of
aneurysm patients in the low-risk group for the Harada risk
score precluded calculation of a C statistic, but NRI could still
Figure. Histogram of baseline maximum z score (zMax) for our cohort (n=261).
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be estimated. C statistics for the bivariate models including
Kobayashi, Sano, and Egami risk scores were 0.83 (95%
conﬁdence interval, 0.74–0.91), 0.77 (95% conﬁdence inter-
val, 0.63–0.90) and 0.79 (95% conﬁdence interval, 0.69–
0.89), respectively (Table 4); increases in areas under the
curve were not statistically signiﬁcant. NRI when the
Kobayashi, Sano, and Egami risk scores were added to
baseline zMax was low, indicating that addition of these risk
scores did not improve our ability to predict CAA beyond zMax
alone.
Laboratory components of the risk scores and demo-
graphic characteristics were analyzed for association with
CAA. Patients with CAA at 4 to 8 weeks after fever onset,
compared with those without CAA, had higher white blood cell
counts and C-reactive protein as well as lower albumin
(Table S2). Patients of young age at fever onset (≤6 months
and <1 year) compared with older children were signiﬁcantly
more likely to develop CAA, and Asian children compared with
other races were also signiﬁcantly more likely to develop CAA
(Table S2).
In multivariable logistic regression, inclusion of Asian race
with baseline echo zMax ≥2.0 increased the C statistic from
0.77 to 0.81; inclusion of age at fever onset ≤6 months
further increased discrimination to 0.85. Calibration of this
model was satisfactory (Hosmer-Lemeshow, P=0.89). Of
these variables, baseline zMax ≥2 had the highest discrim-
ination for predicting CAA development.
Discussion
KD is the leading cause of acquired heart disease in the
developed world,22 and the development of persistent CAA in
childhood is associated with high morbidity through adult-
hood.2,24,25 Over time, CAA can remodel to normal lumen
diameter (so-called regression) or to smaller dimensions via
myoﬁbroblastic proliferation,26 remain stable, develop ste-
noses, or develop thromboses. Coronary aneurysms, partic-
ularly those that are not giant, may remodel to normal lumen
diameter, but this so-called regression of aneurysms may be
accompanied by abnormalities of vessel wall reactivity and
intimal thickness27–30 as well as cardiovascular events later in
life.31,32 To institute effective therapies early enough to
prevent coronary arterial wall damage and its attendant
morbidity, high-risk children should ideally be identiﬁed at the
time of diagnosis of KD. In the current study, we explored
predictors of CAA at 4 to 8 weeks of illness, when dimensions
Table 4. C Statistics, Incremental AUC, and NRI of Baseline z Scores and Japanese Risk Scores
Net Percentage of Patients
C Statistic
Adding High Risk to
Baseline zMax* ≥2.0 (95% CI)
Increase in
AUC (P Value)
Category-Free
NRI
With CAA, Assigned
Higher Predicted
Risk Per Risk Score, %
Without CAA,
Assigned Lower
Predicted Risk
Per Risk Score, %
Baseline zMax ≥2.0 0.77     
Kobayashi high-risk score 0.57 0.83 (0.74–0.91) 0.03 (P=0.14) 0.26 57.1 31.0
Sano high-risk score 0.53 0.77 (0.63–0.90) 0.02 (P=0.26) 0.17 73.3 56.7
Egami high-risk score 0.54 0.79 (0.69–0.89) 0.01 (P=0.85) 0.11 57.1 68.4
Harada high-risk score Cannot estimate c statistic—no CAA in low risk group 0.72 100 27.6
AUC indicates area under the curve; CAA, coronary artery aneurysm; CI, conﬁdence interval; NRI, category-free net reclassiﬁcation improvement; zMax, maximum z score.
*zMax is the larger of the baseline z scores of the left anterior descending artery and right coronary artery.
Table 3. Baseline zMax and Risk Scores as Predictors of
CAAs at 4 to 8 Weeks
n*
Patients With
CAA, n (%) P Value
Baseline zMax†
<2.0 184 3 (2) <0.001
≥2.0 77 12 (16)
Kobayashi
Low risk (0–3) 163 11 (7) 0.39
High risk (≥4) 83 3 (4)
Sano
Low risk (0–1) 203 11 (5) 0.48
High risk (≥2) 39 3 (8)
Egami
Low risk (0–2) 201 13 (7) 0.74
High risk (≥3) 54 2 (4)
Harada
Low risk (0–3) 88 0 (0) 0.003
High risk (≥4) 170 15 (9)
CAA indicates coronary artery aneurysm; zMax, maximum z score.
*Varying numbers of patients were analyzed for risk scores because not all patients had
complete laboratory data for all scores.
†zMax is the larger of baseline z scores of the left anterior descending artery and right
coronary artery.
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of most aneurysms stabilize or begin to diminish in size and
long-term management guidelines replace acute management
strategies.22 Moreover, children with normal echocardio-
graphic ﬁndings at 4 to 8 weeks rarely have abnormalities
1 year after KD.33,34 We found that zMax ≥2.0 on baseline
echocardiography is highly associated with the presence of
CAA at 4 to 8 weeks of illness, offering a possible imaging
biomarker to improve the outcomes of children with KD.
Our ﬁndings build on earlier reports suggesting that
patients who developed coronary aneurysms had higher
baseline zMax scores. Using data from the Pediatric Heart
Network’s trial of pulsed-dose corticosteroid therapy, McCrin-
dle et al noted that a baseline zMax ≥2.5 predicted subse-
quent z scores ≥2.5 over 5 weeks of follow-up in more than
three quarters of patients.5 Dominguez et al reported that 4 in
5 children who developed coronary aneurysms had coronary
artery abnormalities on initial echocardiogram; coronary
abnormalities were ﬁrst detected at a median of illness day
7 (interquartile range: 5–8 days).4
We also explored whether Japanese risk scores for IVIG
resistance could predict the occurrence of CAA. The
Kobayashi, Sano, and Egami risk scores were each developed
in Japan to identify children at high risk for nonresponse to
IVIG treatment, which in turn is highly associated with the
development of CAA.35–38 These IVIG resistance risk scores
did not accurately predict which children in our cohort
developed CAA, nor did they improve discrimination beyond
that of a baseline zMax ≥2.0 alone in our study population.
Consistent with our data, prior studies have indicated that
these established Japanese scores for IVIG resistance do not
perform well in North American mixed-ethnicity cohorts.19,20
The Harada score was designed to predict CAA rather than
IVIG resistance. Among children with baseline zMax ≥2.0, the
Harada score placed all patients with CAA into the high-risk
group. Historically, the Harada score was constructed to
identify patients who warranted treatment with IVIG at a time
when IVIG treatment was not the standard of care in Japan.18
As such, the cutoff point for high versus low risk was set for
maximum sensitivity, which was recapitulated in our popula-
tion, as we found 100% sensitivity for the Harada score.
Conversely, it had very low speciﬁcity. Because there were no
CAA patients in the low-risk group, the Harada score could not
be tested in a logistic regression model and discrimination
could not be assessed; however, it improved risk prediction in
an NRI analysis. Application of the Harada score in a larger
population may allow for further testing of its performance.
Baseline zMax ≥2.0 had good sensitivity at 80% and
reasonable speciﬁcity at 74%. The Kobayashi, Sano, and
Egami scores had very low sensitivity, which limits their
clinical applicability, given the need to identify at-risk patients.
PPV was low for baseline zMax ≥2.0 and for the risk scores
due to the low prevalence of the outcome of CAA as well as
the expected ﬁnding of regression from a high baseline z
score to a normal z score in some patients. Negative
predictive value was >90% for all variables, as baseline z
score <2.0 and low risk status per the Japanese risk scores
were associated with low probability of developing CAA at 4 to
8 weeks after fever onset.
Using multivariable analysis, we assessed the association
of clinical and laboratory variables in the Japanese risk scores
as well as baseline zMax ≥2.0 with CAA development in our
population. We found that a model consisting of baseline
zMax ≥2.0, age at time of illness onset ≤6 months, and Asian
race provided excellent discrimination, with a C statistic of
0.85. This ﬁnding may provide a clinically useful tool but
requires validation in an independent data set. Furthermore,
the modeling may be limited by the relative rarity of Asian
race in the United States and KD patients aged ≤6 months.
Our analysis had certain limitations. Our study was a
retrospective analysis, which led to variation in timing of
follow-up echocardiograms. Furthermore, the low number of
patients with CAA limited our ability to perform multivariable
analyses or to reliably test the discrimination of larger z
scores. We had limited power to determine whether earlier
diagnosis (ie, on days 3–5) affected the strength of the
predictive value of baseline coronary z scores. Missing
laboratory data diminished the total number of participants
available; therefore, the power of this study to identify
children at increased risk of developing CAA was limited.
Similarly, we excluded 70 patients from the study because
they did not have outcome data from echocardiography at 4
to 8 weeks after illness onset. Because patients with CAA are
more likely to be followed closely, our studied population
might have been skewed toward a more severe phenotype.
Nevertheless, baseline characteristics of the excluded
patients, including baseline z scores, were not signiﬁcantly
different from those of the included patients, making spec-
trum bias somewhat less likely. Baseline coronary artery z
scores might have been associated with later measurements
Table 5. Test Characteristics of Baseline z Scores and Risk
Scores
Sensitivity
(15 With
CAA)
Speciﬁcity
(246 Without
CAA)
Positive
Predictive
Value
Negative
Predictive
Value
Baseline
zMax ≥2.0
80% 74% 16% 98%
Kobayashi high risk 21% 66% 4% 93%
Sano high risk 21% 84% 8% 95%
Egami high risk 13% 78% 4% 94%
Harada high risk 100% 36% 9% 100%
CAA, coronary artery aneurysm; zMax, maximum z score.
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because longitudinal data tend to be correlated; however,
coronary arterial wall enlargement can progress rapidly in
some patients with KD within the ﬁrst 4 to 8 weeks. Patients
with expanding coronary artery dimensions generally received
adjunctive therapies, which could have biased our study
toward less positive results by improving 4- to 8-week
coronary artery outcomes, but none of these additional
therapies have been shown to improve coronary artery
outcomes.39,40 The generalizability of our results may be
somewhat limited in centers that are unable to obtain
echocardiography either prior to or within 48 hours of
receiving IVIG. Future work could include evaluation of
echocardiographic data beyond this time period. Finally,
validation of our ﬁndings is important to avoid unnecessary
escalation of primary treatment in children with KD.
In summary, a baseline zMax ≥2.0 had higher predictive
utility for CAA development than any other variable tested,
including established Japanese risk scores and demographic
and laboratory variables. Moreover, the addition of Japanese
risk scores to baseline zMax did not appreciably improve
discrimination. Because baseline z scores are quantitative
measures that are obtained in the routine care of patients
with KD, our ﬁndings raise the possibility that z scores may be
used as an imaging biomarker for the identiﬁcation of high-
risk KD patients in North American populations, both for
tailoring treatment of individual patients and potentially for
enrollment in therapeutic trials.
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Table S1. Comparison of patients included vs. excluded due to lack of echocardiography at 4-8 
weeks after illness onset 
 Excluded 
(n=70) 
Included (n=261) p value 
Age at Fever Onset (years) 3.6 (1.8, 6.1) 3.2 (1.7, 5.2) 0.28 
Age at Fever Onset: <1 year 7 (10%) 35 (13%) 0.73 
Male Sex 41 (59%) 169 (65%) 0.40 
Hispanic Ethnicity 16 (23%) 35 (13%) 0.13 
Asian Race 12 (17%) 50 (19%) 0.86 
Days of Fever  7 (6, 8) 7 (6, 8) 0.73 
IVIG Retreatment 14 (20%) 67 (26%) 0.35 
Baseline Echo Max z score:     
• <2.5 60 (86%) 206 (79%) 0.52 
• 2.5 to 2.99 3 (4%) 17 (7%)  
• >3.0 7 (10%) 38 (15%)  
 
  
3 
 
Table S2. Demographic and laboratory variables associated with CAA  
at 4-8 weeks after illness onset  
Characteristic CAA (n=15) vs. no CAA (n=246) p value 
White Blood Cell Count (median) 20 WBC/mL vs. 14 WBC/mL,  p=0.002 
C-Reactive Protein (median) 14 mg/dL vs. 8 mg/dL P=0.01 
Albumin (median) 2.9 g/dL vs. 3.4 g/dL  p<0.001 
Age < 1 year 33% (n=5) vs. 12% (n=30) p=0.04 
Age ≤ 6 months 20% (n=3) vs 4% (n=9) p=0.02 
Asian race 47%(n=7) vs. 17% (n=43) p=0.05 
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